
INDP Valuation
Indaptus Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
INDP Relative Valuation
INDP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INDP is overvalued; if below, it's undervalued.
Historical Valuation
Indaptus Therapeutics Inc (INDP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.20. The fair price of Indaptus Therapeutics Inc (INDP) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price:7.12
Fair
-0.45
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Indaptus Therapeutics Inc. (INDP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-0.46
EV/EBIT
Indaptus Therapeutics Inc. (INDP) has a current EV/EBIT of -0.46. The 5-year average EV/EBIT is -0.09. The thresholds are as follows: Strongly Undervalued below -1.81, Undervalued between -1.81 and -0.95, Fairly Valued between 0.77 and -0.95, Overvalued between 0.77 and 1.63, and Strongly Overvalued above 1.63. The current Forward EV/EBIT of -0.46 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Indaptus Therapeutics Inc. (INDP) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Indaptus Therapeutics Inc. (INDP) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Indaptus Therapeutics Inc. (INDP) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Indaptus Therapeutics Inc (INDP) has a current Price-to-Book (P/B) ratio of -2.57. Compared to its 3-year average P/B ratio of 1.37 , the current P/B ratio is approximately -287.78% higher. Relative to its 5-year average P/B ratio of 1.04, the current P/B ratio is about -347.50% higher. Indaptus Therapeutics Inc (INDP) has a Forward Free Cash Flow (FCF) yield of approximately -173.27%. Compared to its 3-year average FCF yield of -100.36%, the current FCF yield is approximately 72.65% lower. Relative to its 5-year average FCF yield of -83.44% , the current FCF yield is about 107.67% lower.
-2.57
P/B
Median3y
1.37
Median5y
1.04
-173.27
FCF Yield
Median3y
-100.36
Median5y
-83.44
Competitors Valuation Multiple
The average P/S ratio for INDP's competitors is 12.63, providing a benchmark for relative valuation. Indaptus Therapeutics Inc Corp (INDP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of INDP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of INDP in the past 1 year is driven by Unknown.
People Also Watch

APDN
Applied DNA Sciences Inc
3.945
USD
+0.90%

SOS
Sos Ltd
1.884
USD
-4.37%

HAO
Haoxi Health Technology Ltd
1.280
USD
+7.56%

PSIG
PS International Group Ltd
0.380
USD
0.00%

GSIW
Garden Stage Ltd
0.118
USD
0.00%

CLRB
Cellectar Biosciences Inc
4.340
USD
0.00%

BCDA
BioCardia Inc
1.920
USD
0.00%

JAGX
Jaguar Health Inc
2.110
USD
+0.48%

LRHC
La Rosa Holdings
5.910
USD
0.00%
FAQ

Is Indaptus Therapeutics Inc (INDP) currently overvalued or undervalued?
Indaptus Therapeutics Inc (INDP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.20. The fair price of Indaptus Therapeutics Inc (INDP) is between to according to relative valuation methord.

What is Indaptus Therapeutics Inc (INDP) fair value?

How does INDP's valuation metrics compare to the industry average?

What is the current P/B ratio for Indaptus Therapeutics Inc (INDP) as of Aug 18 2025?

What is the current FCF Yield for Indaptus Therapeutics Inc (INDP) as of Aug 18 2025?

What is the current Forward P/E ratio for Indaptus Therapeutics Inc (INDP) as of Aug 18 2025?
